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ABSTRACT 
Aim: To investigate the lung tissue response measured with CT after radiotherapy (RT) 
combined with metoclopramide. 
Patients and Methods: Patients with NSCLC (tumour stage IIIA and B), included in a 
multicenter randomised phase III trial investigating the use of metoclopramide as a 
radiosensitising agent, were examined with repetitive post-RT CT scans. The analysis 
comprised data up to 100 days post-RT for a subgroup of 16 patients treated with a total dose 
of 60 Gy given in 1.82 Gy per fraction.  
Results: Large radiation doses to subvolumes were associated with denser lung tissue 
measured with CT (p<0.001). Opposed to this finding, the volume of lung tissue irradiated 
with significant doses (v40Gy) was negatively correlated with the average increase in lung 
tissue density (p=0.003). Patients randomised to metoclopramide injections also experienced 
less increase in lung tissue density (p=0.01). 
Conclusion: There was an increase in the density of irradiated lung tissue with radiation dose 
and time after radiotherapy. Metoclopramide and significant radiation doses to larger lung 
volumes (v40Gy) seemed to protect against fibrosis development. 
 
Key words: Radiotherapy, lung cancer, late toxicity, computed tomography 
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ZUSAMMENFASSUNG 
Ziel: Computertomographische Messung von Strahlenreaktion in Lungengewebe nach 
Strahlentherapie in Kombination mit Metoclopramid. 
Patienten und Methodik: Patienten mit nicht-kleinzelligem Bronchialkarzinom 
(Tumorstadium IIIa und b), inkludiert in eine randomisierte Phase III Multizenterstudie zur 
Untersuchung des strahlensensitivierenden Effektes von Metoclopramid, wurden mit 
wiederholten post-therapie CT`s untersucht. Follow-up Daten 100 Tage nach Beendigung der 
Strahlentherapie einer Untergruppe von 16 Patienten, die mit einer Totaldosis von 60 Gy 
appliziert in Tagesdosis von 1,8 Gy behandelt wurden standen zur Analyse zur Verfügung. 
Ergebnisse: Hohe Strahlendosis gegen Teilvolumina resultierten in höherer CT-Dichte im 
bestrahlten Lungengewebe (p<0,001). Im Gegensatz dazu korrelierte das mit signifikanter 
Dosis bestrahlte Lungenvolumen (V40Gy) negativ mit der Zunahme der CT-Dichte im 
bestrahlten Lungengewebe (p=0,003). Bei Patienten, die in den Therapiarm mit 
Metoclopramid randomisiert wurden registrierte man eine weniger ausgeprägte Zunahme der 
CT-Dichte im bestrahlten Lungengewebe (p=0,01). 
Schlussfolgerung: Wir fanden einen Zusammenhang zwischen der Zunahme von gemessener 
CT-Dichte im bestrahlten Lungengewebe, der applizierten Strahlendosis und der Zeit nach 
Bestrahlung. Metoclopramid und das mit signifikanter Dosis bestrahlte Lungenvolumen 
(v40Gy) scheinen einen protektiven Effekt auf die Entwicklung von Lungenfibrose zu haben. 
 
Schlüsselwörter: Strahlentherapie, Bronchialkarzinom, Spähttoxizitet,   
   Computertomographie
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INTRODUCTION 
In patients with localised, inoperable non-small cell lung cancer (NSCLC), radical 
radiotherapy (RT) is the treatment of choice. Since radical radiotherapy may be limited by 
consequential pneumonitis and lung fibrosis, a better understanding of the relationship 
between the radiation dose and the development of late side effects, is needed [3, 4, 12, 17]. 
Previous studies have established CT as a tool to monitor the development of 
fibrosis/pneumonitis measured as changes in CT density [10, 19]. Dose-effect relationships 
have been derived for breast cancer and lymphoma patients [1, 18], and for patients with lung 
cancer [13, 15]. There are less detailed data describing the time dependency of the density 
changes after RT (post-RT) [14, 16]. Some authors have chosen to investigate populations of 
breast cancer and lymphoma patients, partially because of the well-known obstacles related to 
investigations of late side-effects in lung cancer patients [2, 18]: Firstly, the survival of lung 
cancer patients is low, and consequently, the patient materials are of low figures, and may 
thus be highly selected. Secondly, the lung function is influenced not only by RT, but also by 
tumour progression and other lung diseases frequently present in these patients. Nevertheless, 
certainly also for this patient group, further investigations on post-RT side effects are 
justified. 
The enzyme adenosine diphosphate ribosyl transferase is activated by DNA damaging agents. 
From in vitro studies, metoclopramide has been shown to inhibit this enzyme resulting in 
increased cytotoxic effect of radiation and chemotherapeutic drugs (6, 11). A phase I/II study 
indicated that metoclopramide could be used safely as a radiosensitiser and that the drug 
could have positive treatment effects (8). 
In this retrospective study, the results from an analysis on our institution’s follow-up data 
from a multicentre, randomised phase III study, are presented. The primary goal of the 
multicentre study was to explore the overall survival effect of metoclopramide as a 
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radiosensitiser in the treatment of NSCLC [8]. The present paper concentrates on the 
influence of the radiosensitiser and radiotherapy on normal lung tissue as measured as CT 
density changes.  
 
MATERIALS AND METHODS 
During 1995-1998, 30 NSCLC patients from our institution were enrolled in a multicentre, 
randomised phase III study aimed at investigating the efficacy, safety and tolerability of 
intramuscular injections of neutralised metoclopramide 100 mg/ml (Neu-SensamideTM) as a 
radiosensitising agent [6]. Neu-SensamideTM was produced by Oxigene Europe AB. 
Inclusion criteria were inoperable NSCLC, squamous cell carcinoma, stage IIIA and IIIB, age 
>30 years and Karnofsky performance scale ≥ 80. The local ethics committee approved the 
protocol, and all participating patients gave informed consent before entering the study. All 
available follow-up data were transferred to the central study group at Oxigene Europe AB in 
Lund, Sweden for later analysis and publication. The multi-centre study was closed 
prematurely due to financial matters. No follow-up data have been published from the central 
study group. 
Sixteen of the 30 patients from our hospital had sufficient data for a local analysis, i.e. 
complete radiotherapy records and CT examinations. Three of the 16 patients were female 
and the median age was 68 years (range 46-81 years). The remainder 14 patients had 
insufficient follow-up data (partly because of withdrawal from the study related to rapid 
disease progression during or shortly after radiotherapy and partly because of inadequate RT 
files).  
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Radiosensitiser 
Seven patients were randomised to receive intramuscular injections of neutralised 
metoclopramide, 2 mg/kg given 1 hour prior to RT, 3 times per week. Four patients complied 
with the protocol, one patient was not given the sensitiser the last week and two patients 
refused to continue with the sensitiser after few injections due to side-effects (fatigue, muscle 
pain, headache and indigestion).  
 
Radiotherapy 
All patients were given megavoltage (6-15 MV) conformal RT applying 2-4, usually 3, 
radiation fields. The ICRU central axis dose was 60 Gy given in 1.82 Gy per fraction 5 days 
per week. The RT dose planning was performed with Treatment Management System v3.1 
(Helax) based on CT scans acquired with 10 mm slice thickness and 10 mm distance between 
the slices. The clinical target volume comprised the gross tumour volume (GTV) plus a 10 
mm margin accounting for subclinical disease. The multi-leaf collimators were set to obtain 
an additional margin of minimum 5-10 mm, and normally 20 mm to account for set-up errors 
and penumbra. Dose-volume histograms (DVH) of both lungs as a single organ, and only the 
affected lung excluding the GTV were calculated. All doses presented in this study have been 
corrected according to the LQ formula with α/β = 3 Gy for late side effects and dose per 
fraction equal to 2 Gy [7]. 
 
Follow-up CT scans 
For each patient, follow-up CT scans were intended to be performed 12 and 16 weeks after 
the start of RT (i.e. approximately 35 and 65 days after the end of RT lasting 6.5 weeks). In 
addition, several patients had extra diagnostic post-RT CT scans related to suspected tumour 
progression. After advice from our statistician (DTK), we chose to set a cut-off at 100 days 
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when plotting the data and 90 days for the statistical analysis. A median number of 2.5 CT 
examinations per patient, were available (Table 1). CT scans were performed with Cytec 3000 
(General Electrics) in a private radiology clinic. The Cytec 3000 was a sequential CT scanner. 
Normally, the slice thickness was 5mm. 
We chose to present radiation-induced alterations in lung tissue density as changes in the Air-
filled fraction (fair) according to [18]:  
 
fair = 1 - ρ = -0.001⋅NCT 
 
where ρ is the electron density relative to water and NCT is the measured CT number in 
Hounsfield units. The advantage of fair, is that the relative effect seldom attains values over 
100% in contrast to the relative change in tissue density, ρ [18]. Volumes of interests (VOI) 
for CT number measurements were defined on the RT planning computer. VOIs identified 
normal lung tissue in regions of homogeneous dose close to the tumour and were delineated 
on 3 adjacent CT slices with the middle slice containing the ICRU central axis dose. VOIs 
corresponding to regions covered by either 1 or several radiotherapy fields were chosen for 
each patient (Figure 1). The VOI size was typically 30-100 cm3. The 2 Gy equivalent mean 
dose and whether the VOI was anteriorly, centrally or posteriorly located, were recorded. The 
standard deviation (SD) of the VOI dose distribution was always lower than 10%. A median 
number of 3 VOIs for each patient were defined (Table 1). 
Hard-copy RT planning CT images of the VOI were compared with post-RT CT images. 
Corresponding CT images were identified by visually comparing bony and soft tissue 
anatomy, and the VOI could thus be digitally delineated on post-RT CT images. The overall 
mean CT number of the VOI was obtained from multiple small circular areas covering the 
VOI (Figure 1). 
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Ideally, the fair obtained after RT should have been normalised according to the individual’s 
baseline value obtained prior to RT (pre-RT). Unfortunately, it was not possible to obtain the 
baseline CT numbers from the images in the RT planning system. Therefore, the fair was 
normalised according to a global fair of 0.802, the mean fair from all lung VOIs receiving a 
radiation dose less than 8 Gy. To investigate the uncertainty of this normalisation procedure, 
data from The Netherlands Cancer Institute were used. These data included fair of low-dose 
(<8 Gy) areas of the lung from both pre-RT CT scans and 3-4 months post-RT. Thus, the 
ideal normalisation method could be compared with the method applied in the present study. 
The uncertainty introduced by not having access to the baseline fair is measured to be 4% 
(R2=0.96; Figure 2).  
 
Statistics 
To evaluate the reduction in Air-filled fraction the measurement times were pooled: within 30 
days, 31-60 days and 61-90 days after end of RT. A repeated measurement analysis of 
variance was undertaken using the highest radiation (>40 Gy) dose to the VOI for each time 
interval, whether radiosensitiser dose was administered or not, CT post-RT examination time 
and VOI location (central, anterior, posterior) as explanatory variables.  
p-values from 2-sided tests are presented, and should be considered hypothesis generating as 
no power calculations had been performed for the comparisons reported in this paper. The 
data were analysed with SPSS v10.1.0 and SAS v.9.1.3. 
 
RESULTS 
Air-filled fraction 
The impact of the radiosensitiser and the radiation dose to the course of the Air-filled fraction 
(fair), has been visualised in plots for each patient according to whether the patient received 
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radiosensitiser or not. The reduction in fair increased with radiation dose (p<0.001), and the 
effect was more pronounced for those patients not given metoclopramide (p=0.01; Figure 3). 
The normal lung volume (both lungs delineated) irradiated with significant radiation doses 
(20-60 Gy) was negatively correlated with the reduction in fair. The most significant parameter 
was v40Gy (p=0.003; Figure 4). The time dependence of fair was analysed using an interaction 
variable; time and whether metoclopramide was given or not. The reduction in fair increased 
with the time interaction variable (p=0.04; Figure 5). There was a larger reduction in fair for 
those VOIs located in the posterior position in the lung (p=0.01). There was no significant 
difference in fair values comparing the central with the anterior position (p=0.17). 
 
DISCUSSION 
Air-filled fraction 
In the present study we found that the density change (ρ) in the lung measured as an Air-filled 
fraction (fair=1-ρ) change, was dependent on radiation dose. Normal lung tissue irradiated 
with more than 30 Gy was denser 50-100 days after treatment compared to tissue irradiated 
with a smaller doses (Figure 3a). This has also been demonstrated in previous studies. Theuws 
et al. [18] found that the effect measured as a relative change in fair attained values 
significantly different from zero for doses larger than 20 Gy. Their results were derived from 
a material of lymphoma and breast cancer patients but were also confirmed in a study by 
Seppenwoolde et al for NSCLC patients [15]. In a study by Boersma et al., the dose-effect 
relation increased from zero effect at approximately 30 Gy (1). Rosen et al. found a threshold 
for physician-identified radiographic fibrosis at 30-35 Gy, but significant density changes 
were also detected for smaller doses [13].  
Opposed to the positive correlation between local radiation dose to smaller lung volumes, 
there was a negative correlation between the normal lung volumes irradiated with significant 
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doses (v40Gy) and the reduction in fair. A possible explanation is an antitumour effect of the 
radiotherapy making the conditions for the normal lung tissue more favourable. 
The CT examinations were performed at various time points post-RT but due to the limited 
patient number, an exact quantification of the relationship between reduction in fair and time, 
was not possible. Skoczylas et al. [16] measured a change in optical density on follow-up x-
rays of breast cancer patients treated with RT. These investigators found a monotonous 
increase in effect from 1 month reaching a plateau at 4-5 months and then decreasing 
moderately at 8-10 months. These findings are in agreement with a CT study by Rotstein et 
al., examining breast cancer patients at 3 and 9 months after RT [14].  
The decrease in fair was significantly larger for the posterior 1/3 of the lung. All patients were 
examined and treated in the supine position. Theuws et al. have demonstrated this effect 
previously [18]. Their explanation was a gravity-dependent density gradient causing a relative 
increase in lung mass (oedema) in the posterior region after irradiation. 
There was a statistically significant association between high doses of metoclopramide, and 
the least reductions in fair. Animal experiments have reported no increase in effects on normal 
tissue when combining RT with metoclopramide [11]. A possible explanation for the 
relationship between metoclopramide dose and fair, is an antitumour effect similar to the 
negative correlation between normal lung volumes encompassed by the 40 Gy isodose (v40Gy) 
and the reduction in fair. The tumours were mostly centrally located (stage IIIA and IIIB), and 
the patients enduring the drug treatment, could get increased blood perfusion and airflow to 
the neighbouring normal tissues in the lung. These effects of tumour shrinkage have been 
shown by De Jaeger et al and Seppenwoolde et al. [5, 15]. The resulting improved 
physiological conditions after RT could make the lung tissue more resistant to development of 
fibrosis/pneumonitis. Tumour volumes before and after RT could have elucidated our data 
further. Regrettably, tumour volumes were not available in the present material.  
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In conclusion, there was an increase in the density of lung tissue with radiation dose and time 
after radiotherapy. This effect was more pronounced for the posterior lung volumes. 
Metoclopramide and irradiation of large lung volumes with significant doses seemed to 
protect against fibrosis/pneumonitis development. However, the number of patients in the 
analysis was low. Therefore, the results must be interpreted with caution. 
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Patient ID Metoclopramide 
(mg) 
Mean Lung Dose 
(Gy) 
# post-RT CT #CT-VOI 
1 3198 NA 2 3 
2 2160 18.2 3 3 
3 1920 21.5 3 3 
4 0 16.4 3 4 
5 616 16.3 1 2 
6 0 15.9 3 3 
7 0 17.6 3 2 
8 320 19.3 2 4 
9 0 NA 1 3 
10 2160 19.8 3 2 
11 0 9.8 3 2 
12 0 NA 2 4 
13 0 11.1 2 2 
14 0 13.3 2 4 
15 0 22.6 1 3 
16 1800 10.6 3 3 
  Mean Dose = 16.3 
Gy 
#CT = 37 #VOI = 47 
 
Table 1: Radiosensitiser dose, mean radiation dose to both lungs, frequency of CT scans and 
number of VOIs per patient. 
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Tabelle 1: Radiosentiziser Dosis, mittlere Lungendosis, Anzahl durchgeführter CT 
Untersuchungen und Anzahl VOI’s pro Patient. 
 
 
 17 
LEGENDS 
 
Figure 1: The CT number of each VOI was calculated as the mean CT number of multiple 
circular regions covering the VOI.  
 
Figure 2: Data from Netherlands Cancer Institute (NCI) demonstrating the uncertainty 
introduced by not having access to the pre-RT (baseline) CT examination. The relative 
reduction in Air-filled fractions without baseline have been normalised according to the mean 
CT number given less than 8 Gy, as in the present study. The NCI data are derived from 129 
volumes in 14 patients. 
 
Figure 3: The relative reduction in Air-filled fraction (fair) as a function of radiation dose 50-
100 days post-RT. a) Patients not given metoclopramide (n=9). b) Patients given 
metoclopramide (n=7). In the case of > 1 VOI, the mean fair was used. 
 
Figure 4: The relative reduction in Air-filled fraction (fair) averaged over VOI>40 Gy and time 
50-100 days, as a function of v40Gy, the normal lung volume fractions irradiated with more 
than 40 Gy. The Pearson´s correlation coefficient was R2=0.56 (n=13). 
 
Figure 5: The relative reduction in Air-filled fraction (fair) for VOI>40 Gy, as a function of 
time after end of radiotherapy schedule. In the case of > 1 VOI for a specific time, the mean 
fair was used. a) Patients not given metoclopramide (n=9). b) Patients given metoclopramide 
(n=7). 
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ABBILDUNGEN 
 
Abbildung 1: Die Hounsfield-Einheiten für jedes einzelne VOI berechnet sich aus der 
mittleren Hounsfield-Einheiten zirkulärer Regionen über jedem VOI. 
  
Abbildung 2: Daten des niederländischen Krebs Institus (NCI) beschreiben Unsicherheiten 
die mit den nicht zugänglichen pretherapeutischen CT- Untersuchungen zusammenhängen. 
Wenn pretherapeutische CT- Daten fehlen, so ist die relative Reduktion der Air-filled Fraction 
(fair) der Gruppe < 8 Gy, wie auch in unserer aktuellen Studie, im Verhältnis zur mittleren 
Hounsfield-Einheiten normalisiert. Die niederländischen Daten wurden aus 129 Volumina 
von 14 Patienten generiert.  
 
Abbildung 3: Die relative Reduktion der Air-filled fraction (fair) als Funktion der Strahlendose 
50-100 Tage nach Strahlentherapie. a) Patienten ohne Metoclopramid (n=9). b) Patienten mit 
Metoclopramid (n=7). Im Falle von > 1 VOI, wurde die mittlere fair benutzt. 
 
Abbildung 4: Relative Reduktion der Air-filled fraction (fair) für VOI > 40 Gy und Zeit 50 -
100 Tage als Funktion von V40Gy, normales Lungevolumen bestrahlt mit mehr als 40 Gy. 
Pearsons Korrelationskoeffizient R2=0,56 (n=13). 
 
Abbildung 5: Relative Reduktion der Air-filled fraction (fair) für VOI > 40 Gy als Funktion 
der Zeit nach Strahlentherapie. Im Falle von > 1 VOI für eine gegebene Zeit, wurde die 
mittlere fair benutzt. a) Patienten ohne Metoclopramid (n=9). b) Patienten mit Metoclopramid 
(n=7).  
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Fig3a:
a) No metoclopramide administrated
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Fig3b:
b) Metoclopramide administrated
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Fig4:
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Fig5a:
a) No metoclopramide administrated
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Fig5b:
b) Metoclopramide administrated
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